NICE, in collaboration with other international health technology assessment agencies, has published a new report which ...

For information the company have advised that they will no longer be making a submission, or making this gene therapy available in the UK. Therefore, in collaboration with the company, NICE has ...

There is a simple discount patient access scheme for vamorolone. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee C. Committee members are asked to declare any interests in the technology being ...

Vamorolone is recommended, within its marketing authorisation, as an option for treating Duchenne muscular dystrophy (DMD) in people 4 years and over. Vamorolone is only recommended if the company ...

This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'Inputs and eligible population' and 'Unit costs' worksheets in the template to reflect ...

Vamorolone (Agamree, Santhera) is indicated for 'the treatment of Duchenne muscular dystrophy (DMD) in patients aged 4 years and older'. The anticipated list price of vamorolone is £4,585.87 per 100 ...

Tools to help you put the guidance into practice.

Section 7 of the National Institute for Health and Care Excellence (Constitution and Functions) and the Health and Social Care Information Centre (Functions) Regulations 2013 requires integrated care ...

Vamorolone (Agamree) is available on the NHS as a possible treatment for Duchenne muscular dystrophy (DMD) in people 4 years and over. Is this treatment right for me? Your healthcare professionals ...